Physicochemical and Pharmacokinetic characterization of amorphous solid dispersion of tranilast with enhanced solubility in gastric fluid and improved oral bioavailability

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 4, 2012, Pages 379-387

  Onoue, Satomi ^a   Kojo, Yoshiki ^a   Aoki, Yosuke ^a   Kawabata, Yohei ^a   Yamauchi, Yukinori ^b   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b MATSUYAMA UNIVERSITY   (Japan)

Author keywords

Amorphous; Bioavailability; Dissolution; Solid dispersion; Tranilast

Indexed keywords

CHEMICAL COMPOUND; COPOLYMER; CRYSTALLINE TL; EUDRAGIT; EUDRAGIT EPO; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; PLACEBO; POLYMER; POLYVINYLPYRROLIDONE POLYVINYLACETATE COPOLYMER; TRANILAST; UNCLASSIFIED DRUG;

AMORPHOUS SOLID DISPERSION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISPERSION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; RAT; STOMACH JUICE; TEMPERATURE SENSITIVITY; THERMAL ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WETTABILITY;

EID: 84865398523     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-101     Document Type: Article

References (21)

1. Koda, A., Nagai, H., Watanabe, S., Yanagihara, Y. and Sakamoto, K.: Inhibition of hypersensitivity reactions by a new drug, N(3$,4$-dimethoxycinnamoyl. anthranilic acid (N-5$). J. Allergy Clin. Immunol., 57: 396-407 (1976).
2. Suzawa, H., Kikuchi, S., Ichikawa, K. and Koda, A.: Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn. J. Pharmacol., 60: 85-90 (1992).
3. Konneh, M.: Tranilast Kissei Pharmaceutical. IDrugs, 1: 141-146 (1998).
4. Ikeda, H., Inao, M. and Fujiwara, K.: Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem. Biophys. Res. Commun., 227: 322-327 (1996).
5. Uno, M., Kurita, S., Misu, H., Ando, H., Ota, T., Matsuzawa-Nagata, N., Kita, Y., Nabemoto, S., Akahori, H., Zen, Y., Nakanuma, Y., Kaneko, S. and Takamura, T.: Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. Hepatology, 48: 109-118 (2008).
6. Mori, H., Kawada, K., Zhang, P., Uesugi, Y., Sakamoto, O. and Koda, A.: Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int. Arch. Allergy Appl. Immunol., 95: 195-201 (1991).
7. Mori, H., Tanaka, H., Kawada, K., Nagai, H. and Koda, A.: Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis. Jpn. J. Pharmacol., 67: 279-289 (1995).
8. Izumi, K., Mizokami, A., Li, Y. Q., Narimoto, K., Sugimoto, K., Kadono, Y., Kitagawa, Y., Konaka, H., Koh, E., Keller, E. T. and Namiki, M.: Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate, 69: 1222-1234 (2009).
9. Nie, L., Oishi, Y., Doi, I., Shibata, H. and Kojima, I.: Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2{pipe})-permeable channel. Cell Calcium, 22: 75-82 (1997).
10. Noguchi, N., Kawashiri, S., Tanaka, A., Kato, K. and Nakaya, H.: Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol., 39: 240-247 (2003).
11. Kawabata, Y., Yamamoto, K., Debari, K., Onoue, S. and Yamada, S.: Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. Eur. J. Pharm. Sci., 39: 256-262 (2010).
12. The Society of Japanese Pharmacopoeia: Tranilast. Japanese Orange Book No. 12 (Approved drug products with therapeutic equivalence evaluations), Tokyo, Yakuji Nippo Ltd., 2002, p 171.
13. Joe, J. H., Lee, W. M., Park, Y. J., Joe, K. H., Oh, D. H., Seo, Y. G., Woo, J. S., Yong, C. S. and Choi, H. G.: Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int. J. Pharm., 395: 161-166 (2010).
14. Chiou, W. L. and Riegelman, S.: Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci., 60: 1281-1302 (1971).
15. Vogt, F. G., Cohen, D. E., Bowman, J. D., Spoors, G. P., Zuber, G. E., Trescher, G. A., Dellöorco, P. C., Katrincic, L. M., Debrosse, C. W. and Curtis Haltiwanger, R.: Structural analysis of polymorphism and solvation in tranilast. J. Pharm. Sci., 94: 651-665 (2005).
16. Vasconcelos, T., Sarmento, B. and Costa, P.: Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today, 12: 1068-1075 (2007).
17. Friesen, D. T., Shanker, R., Crew, M., Smithey, D. T., Curatolo, W. J. and Nightingale, J. A.: Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm., 5: 1003-1019 (2008).
18. Ren, F., Jing, Q., Tang, Y., Shen, Y., Chen, J., Gao, F. and Cui, J.: Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev. Ind. Pharm., 32: 967-972 (2006).
19. Leuner, C. and Dressman, J.: Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm., 50: 47-60 (2000).
20. Yada, S., Ohya, M., Ohuchi, Y., Hamaura, T., Wakiyama, N., Usui, F., Kusai, A. and Yamamoto, K.: Solid phase transition of CS-891 enantiotropes during grinding. Int. J. Pharm., 255: 69-79 (2003).
21. Savolainen, M., Heinz, A., Strachan, C., Gordon, K. C., Yliruusi, J., Rades, T. and Sandler, N.: Screening for differences in the amorphous state of indomethacin using multivariate visualization. Eur. J. Pharm. Sci., 30: 113-123 (2007).